Titre du document / Document title

Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions

Auteur(s) / Author(s)

METZ D. C. ⁽¹⁾ ; COMER G. M. ⁽²⁾ ; SOFFER E. ⁽²⁾ ; FORSMARK C. E. ⁽³⁾ ; CRYER B. ⁽⁴⁾ ; CHEY W. ⁽⁵⁾ ; PISEGNA J. R. ⁽⁶⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Medicine, Division of Gastroenterology, University of Penn sylvania Medical Center, Philadelphia, PA, ETATS-UNIS
⁽²⁾ Wyeth Research, Collegeville, PA, ETATS-UNIS
⁽³⁾ Division of Gastroenterology, University of Florida, Gainesville, FL, ETATS-UNIS
⁽⁴⁾ Division of Gastroenterology, Dallas Veterans Affairs Medical Center, Dallas, TX, ETATS-UNIS
⁽⁵⁾ Rochester Institute for Digestive Diseases and Sciences, Rochester, NY, ETATS-UNIS
⁽⁶⁾ Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and University of California Los Angeles School of Medicine, Los Angeles, CA, ETATS-UNIS

Résumé / Abstract

Background Zollinger-Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long-term maintenance. Aims The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published. This study extends the initial observations to 3 years. Methods The primary efficacy end point for this report was the control of gastric acid secretion in the last hour before the next dose of oral pantoprazole (acid output of <10 mmol/h; <5 mmol/h in subjects with prior acid-reducing surgery). Dose titration was permitted to a maximum of 240 mg per 24 h. Results Twenty-four subjects completed the study. The acid output of 28 of 34 subjects was controlled at initial enrolment. The mean acid output rates were <10 mmol/h throughout the 36 months of treatment for 90-100% of the patients. The majority of the patients were controlled with b.d. doses of 40 or 80 mg pantoprazole at 36 months (acid output was controlled in 24 of 24 subjects). Pantoprazole was generally well tolerated with minimal adverse events reported. Conclusions Maintenance oral pantoprazole therapy up to 3 years at dosages of 40-120 mg b.d. was effective and well tolerated in patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

Revue / Journal Title

Alimentary pharmacology & therapeutics   ISSN 0269-2813 

Source / Source

2006, vol. 23, n^o3, pp. 437-444 [8 page(s) (article)] (24 ref.)

Langue / Language

Anglais

Editeur / Publisher

Blackwell, Oxford, ROYAUME-UNI  (1987) (Revue)

Mots-clés anglais / English Keywords

Gastrinoma ; Pancreatic disease ; Secretory tumor ; Gastric disease ; Endocrinopathy ; Digestive diseases ; Proton pump inhibitor ; Enzyme inhibitor ; Enzyme ; Hydrolases ; H⁺/K⁺-exchanging ATPase ; Benzimidazole derivatives ; Antiulcer agent ; Antisecretory agent ; Zollinger Ellison syndrome ; Human ; Efficiency ; Pantoprazole ; Oral administration ;

Mots-clés français / French Keywords

Gastrinome ; Pancréas pathologie ; Tumeur sécrétante ; Estomac pathologie ; Endocrinopathie ; Appareil digestif pathologie ; Inhibiteur pompe proton ; Inhibiteur enzyme ; Enzyme ; Hydrolases ; H⁺/K⁺-exchanging ATPase ; Benzimidazole dérivé ; Antiulcéreux ; Antisécrétoire ; Zollinger Ellison syndrome ; Homme ; Efficacité ; Pantoprazole ; Voie orale ;

Mots-clés espagnols / Spanish Keywords

Gastrinoma ; Páncreas patología ; Tumor secretante ; Estómago patología ; Endocrinopatía ; Aparato digestivo patología ; Inhibidor bomba protón ; Inhibidor enzima ; Enzima ; Hydrolases ; H⁺/K⁺-exchanging ATPase ; Benzimidazol derivado ; Antiulceroso ; Antisecretorio ; Zollinger Ellison síndrome ; Hombre ; Eficacia ; Pantoprazol ; Vía oral ;

Localisation / Location

INIST-CNRS, Cote INIST : 21831, 35400013466959.0110